Abbott, mAbxience To Commercialize Several Biosimilars Focusing On Oncology, Women's Health, And Respiratory Diseases In Emerging Markets In Latin America, Southeast Asia, Middle East, And Africa. First Molecules Are Expected To Launch In 2025
Portfolio Pulse from Benzinga Newsdesk
Abbott Laboratories (ABT) and mAbxience have announced a partnership to commercialize several biosimilars focusing on oncology, women's health, and respiratory diseases in emerging markets in Latin America, Southeast Asia, Middle East, and Africa. The first molecules are expected to launch in 2025.

September 20, 2023 | 12:19 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Abbott's partnership with mAbxience to commercialize biosimilars in emerging markets could potentially increase its market share and revenues in the long term. However, the first launch is not expected until 2025, so the short-term impact on the stock is likely to be limited.
The partnership with mAbxience could potentially increase Abbott's market share and revenues in the long term as they are targeting emerging markets with high growth potential. However, as the first launch is not expected until 2025, the short-term impact on the stock is likely to be limited. Therefore, the score is neutral.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100